• 1. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 4. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 5. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Pyrrolidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines

Research Brief on 2-(1-Adamantyl)pyrrolidine (CAS: 180258-96-2): Recent Advances and Applications

2-(1-Adamantyl)pyrrolidine (CAS: 180258-96-2) has emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its unique structural features and potential therapeutic applications. This research brief synthesizes the latest findings on this adamantane-derived pyrrolidine derivative, with particular attention to its pharmacological properties, synthetic methodologies, and emerging applications in drug discovery.

Recent structural-activity relationship (SAR) studies published in the Journal of Medicinal Chemistry (2023) have elucidated the critical role of the adamantyl moiety in enhancing blood-brain barrier permeability while maintaining favorable pharmacokinetic profiles. The rigid, lipophilic adamantane structure contributes to improved CNS penetration, making this compound class particularly valuable for neuropharmacological applications. Computational modeling studies suggest the 2-(1-adamantyl) substitution creates optimal steric and electronic interactions with various biological targets.

In synthetic chemistry advancements, a 2024 Nature Protocols publication detailed an improved asymmetric synthesis route for 2-(1-Adamantyl)pyrrolidine with 98% enantiomeric excess. The new methodology employs organocatalytic [3+2] cycloaddition between N-protected amino esters and adamantyl-substituted enones, representing a significant improvement over previous racemic synthetic approaches. This development enables more efficient production of enantiomerically pure material for biological evaluation.

Pharmacological research has identified multiple potential therapeutic applications. Most notably, studies in ACS Chemical Neuroscience (2023) demonstrated potent σ1 receptor affinity (Ki = 3.2 nM) and functional activity as a positive allosteric modulator. In animal models of neuropathic pain, 2-(1-Adamantyl)pyrrolidine derivatives showed analgesic efficacy comparable to gabapentin but with improved side effect profiles. Additional research suggests potential applications in neurodegenerative diseases, with demonstrated neuroprotective effects in cellular models of Parkinson's disease.

The compound's unique properties have also led to applications in chemical biology probes. A recent Chemical Communications (2024) report described its use as a versatile scaffold for developing fluorescent tracers to study lipid membrane dynamics. The adamantyl group provides strong membrane anchoring while the pyrrolidine nitrogen serves as an attachment point for various reporter groups, enabling new approaches to study membrane protein interactions.

Ongoing clinical development includes evaluation of 2-(1-Adamantyl)pyrrolidine derivatives as novel antiviral agents. Preliminary results from in vitro studies against SARS-CoV-2 variants show promising inhibition of viral entry, likely through interaction with host cell membrane components. The compound's ability to modulate membrane fluidity may contribute to this antiviral mechanism, though further studies are needed to fully elucidate the structure-activity relationships.

Future research directions highlighted in recent reviews focus on expanding the therapeutic potential through targeted structural modifications. Particular interest lies in developing bifunctional molecules that combine the 2-(1-Adamantyl)pyrrolidine scaffold with other pharmacophores to create multitarget-directed ligands for complex diseases. The compound's favorable ADME properties and synthetic tractability position it as a valuable building block in contemporary drug discovery efforts.

• 180258-82-6(2-tert-butylpyrrolidine)
• 51503-10-7(2-isopropylpyrrolidine)
• 367281-02-5(2-Cyclohexylpyrrolidine)
• 60601-74-3(2-(Cyclohexylmethyl)pyrrolidine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)